SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF
THE
SECURITIES EXCHANGE ACT OF 1934
Date
of
Report (Date of earliest event reported): May 30, 2007 (May 23,
2007)
CHEMBIO
DIAGNOSTIC, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
0-30379
|
88-0425691
|
||
|
(State
or other jurisdiction
|
(Commission
File Number)
|
(IRS
Employer
|
||
|
of
Incorporation)
|
Identification
Number)
|
|||
|
3661
Horseblock Road
|
||||
|
Medford,
NY 11763
|
||||
|
(Address
of principal executive offices)
|
||||
|
631-924-1135
|
||||
|
(Registrant’s
Telephone Number)
|
N/A
(Former
name or former address, if changed since last report)
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
o Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
ITEM
7.01. Regulation FD Disclosures.
On
May
23, 2007 the Registrant issued the press release titled “Chembio and Infectious
Disease Research Institute Collaborating on Development of Rapid Tests for
Leishmaniasis and Leprosy” included herein as Exhibit 99.1.
On
May
30, 2007 the Registrant issued the press release titled “Chembio Appoints Robert
L. Aromando, Jr. Senior Vice President, Commercial Operations” included herein
as Exhibit 99.2.
ITEM
9.01. Financial Statements and Exhibits
|
(d)
|
Exhibits.
|
|
99.1
|
Press
Release titled “Chembio and Infectious Disease
Research Institute Collaborating on Development of Rapid Tests
for
Leishmaniasis and Leprosy” issued May 23,
2007.
|
|
99.2
|
Press
Release titled “Chembio Appoints Robert L. Aromando,
Jr. Senior Vice President, Commercial Operations” issued May 30,
2007.
|
In
accordance with General Instruction B.2 of Form 8-K, the information in this
Current Report on Form 8-K shall not be deemed “filed” for the purpose of
Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed
incorporated by reference in any filing. This Current Report on Form
8-K does not constitute a determination of whether any information included
herein is material.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned thereunto
duly authorized.
Date: May
30,
2007 Chembio
Diagnostics, Inc.
By:
/s/ Lawrence A.
Siebert
Lawrence
A. Siebert
Chief
Executive Officer